Title: TREATMENT OF LFA-1 ASSOCIATED DISORDERS WITH INCREASING DOSES Inventors: Garovox et al.






Figure 1

Title: TREATMENT OF LFA-1 ASSOCIATED DISORDERS WITH INCREASING DOSES Inventors: Garovoy et al. Genentech Docket No.: P1747R2D1 Sheet 2 of 10

Group	Dose (mg/kg)	_ =	Day 0	Day 28	Day 56
4	0.1/qow	4	23.6 ± 8.1	-11.3 ± 15.1	-4.6 ± 5.6
<b>m</b>	0.1	9	$21.2 \pm 6.5$	-8.2 ± 15.1	-14.1 ± 17.0
O	0.3*	17	25.6 ± 7.4	-24.5 ± 21.7	-40.4 ± 28.1
۵	0.3-0.6	9	23.8 ± 4.5	-30.1 ± 13.7	-39.6 ± 28.9
ш	0.3-1.0	9	28.1 ± 6.1	-38.6 ± 16.7	-45.4 ± 31.2
Total		39	24.8 ± 6.8	-23.7 ± 20.0	-33.2 ± 28.4

Figure 2

Title: TREATMENT OF LFA-1 ASSOCIATED DISORDERS WITH INCREASING DOSES Inventors: Garovoy et al. Genentech Docket No.: P1747R2D1 Sheet 3 of 10

% Decrease in PASI Score Mean (±S.D) (mg/kg) Dose **Dose Groups** (combined) hu1124

A+B

 $10.3 (\pm 13.9)$ 

 $41.3 (\pm 27.9)$ 

**≥ 0.3** 

C+D+E

.0019

p value

Figure 3

Title: TREATMENT OF LFA-1 ASSOCIATED DISORDERS WITH INCREASING DOSES Inventors: Garovoy et al. Genentech Docket No.: P1747R2D1 Sheet 4 of 10





Figure 4-A






Figure 4-B




Figure 4-C




Figure 4-D




Figure 4-E

Title: TREATMENT OF LFA-1 ASSOCIATED DISORDERS WITH INCREASING DOSES Inventors: Garovoy et al. Genentech Docket No.: P1747R2D1 Sheet 9 of 10

Day 56

	Dose	# of Patient	# of Patients with Decreased Staining	sed Staining
Group (mg/kg)	(mg/kg)	ICAM-1	Ker 16	CD11a
A	0.1/qow	0/4	0/4	0/4
<b>ω</b>	0.1	1/4	1/4	2/4
ပ	0.3	8/12	8/12	12/12
Q	0.3-0.6	3/6	2/2	4/5
Ш	0.3-1.0	3/4	4/4	4/4

Figure 5

Title: TREATMENT OF LFA-1 ASSOCIATED DISORDERS WITH INCREASING DOSES Inventors: Garovoy et al. Genentech Docket No.: P1747R2D1 Sheet 10 of 10

	Dose			S	Study Day	ay		_
Group	(mg/kg)	0	7	14	21	28	35	42
4	A 0.1/qow		,					
œ	0.1		_					
C 0.3	0.3	14	က	_	8	4	8	2
۵	9.0-6.0	∞		-		-		
ш	0.3-1.0	2		-				-
Total		27	4	က	2	5	2	က

Figure 6